News | 02 March 2026
Chennai gets first structured geriatric continuity-of-care programme
Swayam is designed to support elderly patients and their families with seamless access to coordinated medical care
Swayam is designed to support elderly patients and their families with seamless access to coordinated medical care
The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 202
The facility is expected to become operational by FY2028-29
Emcure to distribute Roche's kidney transplant and anemia drugs in India
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
The product addresses a market with approximately $66.8 million in annual sales as of December 2025.
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
For the fourth quarter, revenue surged 47% year-on-year to Rs. 2,510 million, driven by a 23% rise in domestic sales and a 9.3x jump in export sales
The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform
The new patents cover critical advancements in cochlear implant technology
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
The innovative eyedrop targets inflammation and pain following ocular surgery
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
Subscribe To Our Newsletter & Stay Updated
